Novel Imidazole Derivative AOMI: Enhanced Antibacterial/Anti-Biofilm Properties and Mechanistic Insights

The research delves into the creation and assessment of an innovative imidazole derivative, AOMI, which shows remarkable antibacterial and anti-biofilm capabilities.The synthesis and evaluation of 2-(2-(anthracen-9-yl)-5-oxoimidazolidin-1-yl)-1methyl-1H-imidazol-4(5H)-one (AOMI), a new imidazole derivative with strong antibacterial and anti-biofilm capabilities, are investigated in this study using molecular docking experiments.AOMI was created by reacting anthracene-9-carbaldehyde with creatinine to obtain the Schiff base (E)-2-(anthracen-9-ylmethyleneamino)-1-methyl-1Himidazol-4(5H)-one (AMMI).The use of techniques like FTIR, 1 H NMR, and 13 C NMR allowed for the confirmation of the produced compounds' structures.The antibacterial tests showed that AOMI was highly effective against S. aureus and E. coli when mixed with amoxicillin, with inhibition zones as large as 22.25 0.30 mm.It should be noted that AOMI outperformed amoxicillin in terms of anti-biofilm activity and had a minimum inhibitory concentration (MIC) of 200 g/mL.Furthermore, DPPH experiments demonstrated that AOMI exhibited antioxidant activity, with scavenging rates reaching a maximum of 79.10% at the dose that was tested.According to the molecular docking data, there were strong contacts with the target protein's active site residues through electrostatic and hydrogen bonding interactions, as evidenced by a binding energy of -30.5897 kcal/mol and an RMSD value of 2.4709 .We need to learn more about how AOMI works and make more imidazole derivatives since these results suggest that it could be a very good way to treat bacterial infections.